Glaxosmithkline patents expiration
1. Abreva patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5534554 | GLAXOSMITHKLINE | Sucrose ester-C20 to C28 alcohol formulations |
Dec, 2013
(10 years ago) | |
| US4874794 | GLAXOSMITHKLINE | Inflammatory disease treatment |
Apr, 2014
(10 years ago) | |
Drugs and Companies using DOCOSANOL ingredient
Market Authorisation Date: 25 July, 2000
Treatment: Treats cold sores/fever blisters on the face or lips. shortens healing time and duration of symptoms: tingling, pain, burning and/or itching
Dosage: CREAM;TOPICAL
ABREVA family patents
2. Advil Allergy Sinus patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7863287 | GLAXOSMITHKLINE | Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines |
Feb, 2027
(2 years from now) | |
Market Authorisation Date: 19 December, 2002
Treatment: NA
Dosage: TABLET;ORAL
ADVIL ALLERGY SINUS family patents
3. Advil Pm patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8883849 | GLAXOSMITHKLINE | Treatment of sleep disturbances |
Jan, 2022
(2 years ago) | |
| US9155718 | GLAXOSMITHKLINE | Treatment of sleep disturbances |
Jan, 2022
(2 years ago) | |
Drugs and Companies using DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN ingredient
Market Authorisation Date: 21 December, 2005
Treatment: A method of treating a patient suffering from a pain associated sleep disturbance comprising administering a liquid composition formulated inside a soft gel capsule, as claimed, to the patient
Dosage: CAPSULE;ORAL
ADVIL PM family patents
4. Advil Pm patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8263647 | GLAXOSMITHKLINE | Treatment of sleep disturbances |
May, 2022
(1 year, 10 months ago) | |
Drugs and Companies using DIPHENHYDRAMINE CITRATE; IBUPROFEN ingredient
Market Authorisation Date: 21 December, 2005
Treatment: NA
Dosage: TABLET;ORAL
ADVIL PM family patents
5. Agenerase patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5585397 | GLAXOSMITHKLINE | Sulfonamide inhibitors of aspartyl protease |
Dec, 2013
(10 years ago) | |
| US5646180 | GLAXOSMITHKLINE | Treatment of the CNS effects of HIV |
Jul, 2014
(9 years ago) | |
| US5723490 | GLAXOSMITHKLINE | THF-containing sulfonamide inhibitors of aspartyl protease |
Mar, 2015
(9 years ago) | |
| US6730679 | GLAXOSMITHKLINE | Pharmaceutical formulations |
Nov, 2017
(6 years ago) | |
Drugs and Companies using AMPRENAVIR ingredient
Market Authorisation Date: 15 April, 1999
Treatment: Treatment of hiv infection
Dosage: CAPSULE;ORAL; SOLUTION;ORAL
AGENERASE family patents
6. Anoro Ellipta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7361787 | GLAXOSMITHKLINE | Phenethanolamine derivatives for treatment of respiratory diseases |
Mar, 2023
(1 year, 1 month ago) | |
| USRE44874 | GLAXOSMITHKLINE | Phenethanolamine derivatives for treatment of respiratory diseases |
Mar, 2023
(1 year, 1 month ago) | |
| US7498440 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Apr, 2025
(1 year, 1 day from now) | |
| US7439393 | GLAXOSMITHKLINE | Phenethanolamine derivatives for treatment of respiratory diseases |
May, 2025
(1 year, 25 days from now) | |
| US7488827 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Dec, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5873360 | GLAXOSMITHKLINE | Inhalation device |
Feb, 2016
(8 years ago) | |
| US7776895 | GLAXOSMITHKLINE | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases |
Sep, 2022
(1 year, 7 months ago) | |
| US8309572 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Apr, 2025
(1 year, 1 day from now) | |
| US8183257 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Jul, 2025
(1 year, 3 months from now) | |
|
US7439393 (Pediatric) | GLAXOSMITHKLINE | Phenethanolamine derivatives for treatment of respiratory diseases |
Nov, 2025
(1 year, 6 months from now) | |
| US8511304 | GLAXOSMITHKLINE | Medicament dispenser |
Jun, 2027
(3 years from now) | |
| US9333310 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2027
(3 years from now) | |
| US8113199 | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Oct, 2027
(3 years from now) | |
|
US8511304 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Dec, 2027
(3 years from now) | |
| US8161968 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2028
(3 years from now) | |
|
US9333310 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Apr, 2028
(3 years from now) | |
|
US8113199 (Pediatric) | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Apr, 2028
(3 years from now) | |
|
US8161968 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Aug, 2028
(4 years from now) | |
| US8201556 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2029
(4 years from now) | |
| US8534281 | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Mar, 2030
(5 years from now) | |
|
US8534281 (Pediatric) | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Sep, 2030
(6 years from now) | |
| US8746242 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2030
(6 years from now) | |
| US9750726 | GLAXOSMITHKLINE | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
Nov, 2030
(6 years from now) | |
| US11090294 | GLAXOSMITHKLINE | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
Nov, 2030
(6 years from now) | |
|
US8746242 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 18, 2016 |
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2018 |
| M(M-245) | Jun 09, 2022 |
Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient
NCE-1 date: 18 December, 2017
Market Authorisation Date: 18 December, 2013
Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.; Mai...
Dosage: POWDER;INHALATION
ANORO ELLIPTA family patents
7. Arnuity Ellipta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7101866 | GLAXOSMITHKLINE | Anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5873360 | GLAXOSMITHKLINE | Inhalation device |
Feb, 2016
(8 years ago) | |
| US7629335 | GLAXOSMITHKLINE | Anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
| US9333310 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2027
(3 years from now) | |
| US8113199 | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Oct, 2027
(3 years from now) | |
| US8161968 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2028
(3 years from now) | |
|
US9333310 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Apr, 2028
(3 years from now) | |
|
US8113199 (Pediatric) | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Apr, 2028
(3 years from now) | |
|
US8161968 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Aug, 2028
(4 years from now) | |
| US8201556 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2029
(4 years from now) | |
| US8534281 | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Mar, 2030
(5 years from now) | |
|
US8534281 (Pediatric) | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Sep, 2030
(6 years from now) | |
| US8746242 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2030
(6 years from now) | |
|
US8746242 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-290) | Mar 01, 2026 |
| New Strength(NS) | May 17, 2021 |
| New Patient Population(NPP) | May 17, 2021 |
| New Product(NP) | Aug 20, 2017 |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 17 May, 2018
Treatment: Indicated for the once-daily maintenance treatment of asthma as prophylactic therapy in patients aged 12 years of age and older
Dosage: POWDER;INHALATION
ARNUITY ELLIPTA family patents
8. Bactroban patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5569672 | GLAXOSMITHKLINE | Compounds |
Oct, 2013
(10 years ago) | |
| US6025389 | GLAXOSMITHKLINE | Pharmaceutical and veterinary compositions of mupirocin and methods for their preparation |
Oct, 2014
(9 years ago) | |
Drugs and Companies using MUPIROCIN CALCIUM ingredient
Market Authorisation Date: 18 September, 1995
Treatment: Treatment of bacterial infections in the nasal passage of adult patients and health care workers with methicillin resistant s. aureus; Treatment of secondarily infected traumatic skin lesions due to s...
Dosage: OINTMENT;NASAL; CREAM;TOPICAL
BACTROBAN family patents
9. Children's Advil Allergy Sinus patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10238640 | GLAXOSMITHKLINE | Pharmaceutical suspension composition |
May, 2024
(29 days from now) | |
Market Authorisation Date: 24 February, 2004
Treatment: NA
Dosage: SUSPENSION;ORAL
CHILDREN'S ADVIL ALLERGY SINUS family patents
10. Children's Advil-flavored patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10238640 | GLAXOSMITHKLINE | Pharmaceutical suspension composition |
May, 2024
(29 days from now) | |
Drugs and Companies using IBUPROFEN ingredient
Market Authorisation Date: 27 June, 1996
Treatment: NA
Dosage: SUSPENSION;ORAL
CHILDREN'S ADVIL-FLAVORED family patents
11. Epivir-hbv patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE39155 | GLAXOSMITHKLINE | Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis B |
Jul, 2013
(10 years ago) | |
|
USRE39155 (Pediatric) | GLAXOSMITHKLINE | Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis B |
Jan, 2014
(10 years ago) | |
| US5905082 | GLAXOSMITHKLINE | Crystalline oxathiolane derivatives |
May, 2016
(7 years ago) | |
|
US5905082 (Pediatric) | GLAXOSMITHKLINE | Crystalline oxathiolane derivatives |
Nov, 2016
(7 years ago) | |
| US6004968 | GLAXOSMITHKLINE | Pharmaceutical compositions containing lamivudine |
Mar, 2018
(6 years ago) | |
|
US6004968 (Pediatric) | GLAXOSMITHKLINE | Pharmaceutical compositions containing lamivudine |
Sep, 2018
(5 years ago) | |
Drugs and Companies using LAMIVUDINE ingredient
Market Authorisation Date: 08 December, 1998
Treatment: Treatment of hepatitis b infection
Dosage: SOLUTION;ORAL; TABLET;ORAL
EPIVIR-HBV family patents
12. Imitrex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5307953 | GLAXOSMITHKLINE | Single dose dispenser having a piercing member |
Dec, 2012
(11 years ago) | |
|
US5307953 (Pediatric) | GLAXOSMITHKLINE | Single dose dispenser having a piercing member |
Jun, 2013
(10 years ago) | |
| US5554639 | GLAXOSMITHKLINE | Medicaments |
Sep, 2013
(10 years ago) | |
|
US5554639 (Pediatric) | GLAXOSMITHKLINE | Medicaments |
Mar, 2014
(10 years ago) | |
Drugs and Companies using SUMATRIPTAN ingredient
Market Authorisation Date: 26 August, 1997
Treatment: Method of treating migraine
Dosage: SPRAY;NASAL
IMITREX family patents
13. Jesduvroq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11643397 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Jun, 2027
(3 years from now) | |
| US8324208 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Dec, 2028
(4 years from now) | |
| US11117871 | GLAXOSMITHKLINE | Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof |
Mar, 2038
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8815884 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Jun, 2027
(3 years from now) | |
| US8557834 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Jun, 2027
(3 years from now) | |
| US11649217 | GLAXOSMITHKLINE | Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof |
Mar, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 01, 2028 |
Drugs and Companies using DAPRODUSTAT ingredient
NCE-1 date: 01 February, 2027
Market Authorisation Date: 01 February, 2023
Treatment: Treatment of anemia due to chronic kidney disease; A method of treating anemia
Dosage: TABLET;ORAL
JESDUVROQ family patents
14. Malarone patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5998449 | GLAXOSMITHKLINE | Combination of atovaquone with proguanil for the treatment of protozoal infections |
Nov, 2013
(10 years ago) | |
| US6166046 | GLAXOSMITHKLINE | Combination of atovaquone with proguanil for the treatment of protozoal infections |
Nov, 2013
(10 years ago) | |
| US6291488 | GLAXOSMITHKLINE | Preventing protozoal infections |
Nov, 2013
(10 years ago) | |
|
US5998449 (Pediatric) | GLAXOSMITHKLINE | Combination of atovaquone with proguanil for the treatment of protozoal infections |
May, 2014
(9 years ago) | |
|
US6166046 (Pediatric) | GLAXOSMITHKLINE | Combination of atovaquone with proguanil for the treatment of protozoal infections |
May, 2014
(9 years ago) | |
|
US6291488 (Pediatric) | GLAXOSMITHKLINE | Preventing protozoal infections |
May, 2014
(9 years ago) | |
Drugs and Companies using ATOVAQUONE; PROGUANIL HYDROCHLORIDE ingredient
Market Authorisation Date: 14 July, 2000
Treatment: Treatment of protozoal infection; Method of use of atovaquone and proguanil
Dosage: TABLET;ORAL
MALARONE family patents
15. Malarone Pediatric patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6166046 | GLAXOSMITHKLINE | Combination of atovaquone with proguanil for the treatment of protozoal infections |
Nov, 2013
(10 years ago) | |
| US5998449 | GLAXOSMITHKLINE | Combination of atovaquone with proguanil for the treatment of protozoal infections |
Nov, 2013
(10 years ago) | |
| US6291488 | GLAXOSMITHKLINE | Preventing protozoal infections |
Nov, 2013
(10 years ago) | |
|
US5998449 (Pediatric) | GLAXOSMITHKLINE | Combination of atovaquone with proguanil for the treatment of protozoal infections |
May, 2014
(9 years ago) | |
|
US6166046 (Pediatric) | GLAXOSMITHKLINE | Combination of atovaquone with proguanil for the treatment of protozoal infections |
May, 2014
(9 years ago) | |
|
US6291488 (Pediatric) | GLAXOSMITHKLINE | Preventing protozoal infections |
May, 2014
(9 years ago) | |
Drugs and Companies using ATOVAQUONE; PROGUANIL HYDROCHLORIDE ingredient
Market Authorisation Date: 14 July, 2000
Treatment: Treatment of protozoal infection; Method of use of atovaquone and proguanil
Dosage: TABLET;ORAL
MALARONE PEDIATRIC family patents
16. Nicorette patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8323683 | GLAXOSMITHKLINE | Flavoring of drug-containing chewing gums |
Apr, 2028
(4 years from now) | |
| US8940772 | GLAXOSMITHKLINE | Nicotine lozenge composition |
Apr, 2029
(5 years from now) | |
| US8501164 | GLAXOSMITHKLINE | Nicotine lozenge compositions |
Jun, 2029
(5 years from now) | |
Drugs and Companies using NICOTINE POLACRILEX ingredient
Market Authorisation Date: 09 February, 1996
Treatment: NA
Dosage: TROCHE/LOZENGE;ORAL
NICORETTE family patents
17. Ojjaara patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8486941 | GLAXOSMITHKLINE | Phenyl amino pyrimidine compounds and uses thereof |
Jan, 2030
(5 years from now) | |
| USRE48285 | GLAXOSMITHKLINE | N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide |
Jun, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9809559 | GLAXOSMITHKLINE | (N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide |
Jun, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-441) | Sep 15, 2030 |
| New Chemical Entity Exclusivity(NCE) | Sep 15, 2028 |
Drugs and Companies using MOMELOTINIB DIHYDROCHLORIDE ingredient
NCE-1 date: 16 September, 2027
Market Authorisation Date: 15 September, 2023
Treatment: For the treatment of intermediate or high-risk myelofibrosis
Dosage: TABLET;ORAL
OJJAARA family patents
18. Relenza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5360817 | GLAXOSMITHKLINE | Derivatives and analogues of 2-deoxy-2,3-didehydro-N-acetyl neuraminic acid and their use as antiviral agents |
Jul, 2013
(10 years ago) | |
| US6294572 | GLAXOSMITHKLINE | Crystalline N-acetyl neuraminic acid derivatives and process for their preparation |
Dec, 2014
(9 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5648379 | GLAXOSMITHKLINE | Derivatives and analogues of 2-deoxy-2,3-didehydro-n-acetyl neuraminic acid and their use as antiviral agents |
Jul, 2014
(9 years ago) | |
Drugs and Companies using ZANAMIVIR ingredient
Market Authorisation Date: 26 July, 1999
Treatment: Zanamivir for inhalation
Dosage: POWDER;INHALATION
RELENZA family patents
19. Serevent patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5873360 | GLAXOSMITHKLINE | Inhalation device |
Feb, 2016
(8 years ago) | |
|
US5873360 (Pediatric) | GLAXOSMITHKLINE | Inhalation device |
Aug, 2016
(7 years ago) | |
Drugs and Companies using SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 19 September, 1997
Treatment: NA
Dosage: POWDER;INHALATION
SEREVENT family patents
20. Trelegy Ellipta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7101866 | GLAXOSMITHKLINE | Anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
| USRE44874 | GLAXOSMITHKLINE | Phenethanolamine derivatives for treatment of respiratory diseases |
Mar, 2023
(1 year, 1 month ago) | |
| US7498440 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Apr, 2025
(1 year, 1 day from now) | |
| US7439393 | GLAXOSMITHKLINE | Phenethanolamine derivatives for treatment of respiratory diseases |
May, 2025
(1 year, 25 days from now) | |
| US7488827 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Dec, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6878698 | GLAXOSMITHKLINE | Anti-inflammatory androstane derivatives |
Aug, 2021
(2 years ago) | |
| US6759398 | GLAXOSMITHKLINE | Anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
| US7629335 | GLAXOSMITHKLINE | Anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
| US6537983 | GLAXOSMITHKLINE | Anti-inflammatory androstane derivatives |
Aug, 2021
(2 years ago) | |
| US7776895 | GLAXOSMITHKLINE | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases |
Sep, 2022
(1 year, 7 months ago) | |
| US8309572 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Apr, 2025
(1 year, 1 day from now) | |
| US8183257 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Jul, 2025
(1 year, 3 months from now) | |
|
US7439393 (Pediatric) | GLAXOSMITHKLINE | Phenethanolamine derivatives for treatment of respiratory diseases |
Nov, 2025
(1 year, 6 months from now) | |
| US8511304 | GLAXOSMITHKLINE | Medicament dispenser |
Jun, 2027
(3 years from now) | |
| US9333310 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2027
(3 years from now) | |
| US8113199 | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Oct, 2027
(3 years from now) | |
|
US8511304 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Dec, 2027
(3 years from now) | |
| US8161968 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2028
(3 years from now) | |
|
US9333310 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Apr, 2028
(3 years from now) | |
|
US8113199 (Pediatric) | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Apr, 2028
(3 years from now) | |
|
US8161968 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Aug, 2028
(4 years from now) | |
| US8534281 | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Mar, 2030
(5 years from now) | |
|
US8534281 (Pediatric) | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Sep, 2030
(6 years from now) | |
| US8746242 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2030
(6 years from now) | |
| US9750726 | GLAXOSMITHKLINE | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
Nov, 2030
(6 years from now) | |
| US11090294 | GLAXOSMITHKLINE | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
Nov, 2030
(6 years from now) | |
|
US8746242 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2018 |
| New Indication(I-775) | Apr 24, 2021 |
| New Indication(I-843) | Sep 09, 2023 |
| New Strength(NS) | Sep 09, 2023 |
NCE-1 date: 18 December, 2017
Market Authorisation Date: 18 September, 2017
Treatment: The treatment of chronic obstructive pulmonary disease by once-per-day administration of a pharmaceutical formulation comprising fluticasone furoate and a long-acting beta2 adrenoreceptor; The treatme...
Dosage: POWDER;INHALATION
TRELEGY ELLIPTA family patents
21. Tritec patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5456925 | GLAXOSMITHKLINE | Pharmaceutical compositions containing furan derivatives |
Oct, 2012
(11 years ago) | |
| US5601848 | GLAXOSMITHKLINE | Methods for the treatment of gastrointestinal disorders |
Feb, 2014
(10 years ago) | |
| US5629297 | GLAXOSMITHKLINE | Medicament for treating gastrointestinal disorders |
May, 2014
(9 years ago) | |
Drugs and Companies using RANITIDINE BISMUTH CITRATE ingredient
Market Authorisation Date: 08 August, 1996
Treatment: Method of treating peptic ulcer disease caused by campylobacter pyloridis comprising oral administration of 50 to 5,000mg bismuth daily for 3-56 days; Method for treating gi disorders caused by h. pyl...
Dosage: TABLET;ORAL
TRITEC family patents
22. Valtrex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6107302 | GLAXOSMITHKLINE | Guanine derivative |
Jan, 2016
(8 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5879706 | GLAXOSMITHKLINE | Valaciclovir tablets containing colloidal silicon dioxide |
Jan, 2016
(8 years ago) | |
|
US6107302 (Pediatric) | GLAXOSMITHKLINE | Guanine derivative |
Jul, 2016
(7 years ago) | |
|
US5879706 (Pediatric) | GLAXOSMITHKLINE | Valaciclovir tablets containing colloidal silicon dioxide |
Jul, 2016
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-570) | Sep 02, 2011 |
| Pediatric Exclusivity(PED) | Mar 02, 2012 |
| New Patient Population(NPP) | Sep 02, 2011 |
Drugs and Companies using VALACYCLOVIR HYDROCHLORIDE ingredient
Market Authorisation Date: 23 June, 1995
Treatment: Treatment of herpes zoster, treatment of genital herpes, treatment of cold sores, suppression of genital herpes in immunocompetent and hiv-infected individuals, reduction of risk of heterosexual trans...
Dosage: TABLET;ORAL
VALTREX family patents
23. Ventolin Hfa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6596260 | GLAXOSMITHKLINE | Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol |
Aug, 2014
(9 years ago) | |
|
US6596260 (Pediatric) | GLAXOSMITHKLINE | Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol |
Feb, 2015
(9 years ago) | |
| US6558651 | GLAXOSMITHKLINE | Aerosols containing annealed particulate salbutamol and tetrafluoroethane |
Dec, 2016
(7 years ago) | |
|
US6558651 (Pediatric) | GLAXOSMITHKLINE | Aerosols containing annealed particulate salbutamol and tetrafluoroethane |
Jun, 2017
(6 years ago) | |
| US6510969 | GLAXOSMITHKLINE | Valve for aerosol container |
Dec, 2017
(6 years ago) | |
| US6170717 | GLAXOSMITHKLINE | Valve for aerosol container |
Dec, 2017
(6 years ago) | |
| US6966467 | GLAXOSMITHKLINE | Valve for aerosol container |
Dec, 2017
(6 years ago) | |
| US6315173 | GLAXOSMITHKLINE | Valve for aerosol container |
Dec, 2017
(6 years ago) | |
| US6938796 | GLAXOSMITHKLINE | Indicating device |
Jan, 2018
(6 years ago) | |
| US6435372 | GLAXOSMITHKLINE | Delivery system for a medicament and method for the assembly thereof |
Jan, 2018
(6 years ago) | |
| US6161724 | GLAXOSMITHKLINE | Indicating device |
Jan, 2018
(6 years ago) | |
| US6997349 | GLAXOSMITHKLINE | Indicating device |
Jan, 2018
(6 years ago) | |
| US7143908 | GLAXOSMITHKLINE | Indicating device |
Jan, 2018
(6 years ago) | |
| US6431168 | GLAXOSMITHKLINE | Dispenser with doses′ counter |
Jun, 2018
(5 years ago) | |
| US7107986 | GLAXOSMITHKLINE | Dispenser with doses' counter |
Jun, 2018
(5 years ago) | |
|
US6966467 (Pediatric) | GLAXOSMITHKLINE | Valve for aerosol container |
Jun, 2018
(5 years ago) | |
|
US6510969 (Pediatric) | GLAXOSMITHKLINE | Valve for aerosol container |
Jun, 2018
(5 years ago) | |
|
US6315173 (Pediatric) | GLAXOSMITHKLINE | Valve for aerosol container |
Jun, 2018
(5 years ago) | |
|
US6170717 (Pediatric) | GLAXOSMITHKLINE | Valve for aerosol container |
Jun, 2018
(5 years ago) | |
|
US7143908 (Pediatric) | GLAXOSMITHKLINE | Indicating device |
Jul, 2018
(5 years ago) | |
|
US6435372 (Pediatric) | GLAXOSMITHKLINE | Delivery system for a medicament and method for the assembly thereof |
Jul, 2018
(5 years ago) | |
|
US6161724 (Pediatric) | GLAXOSMITHKLINE | Indicating device |
Jul, 2018
(5 years ago) | |
|
US6938796 (Pediatric) | GLAXOSMITHKLINE | Indicating device |
Jul, 2018
(5 years ago) | |
|
US6997349 (Pediatric) | GLAXOSMITHKLINE | Indicating device |
Jul, 2018
(5 years ago) | |
| US7350676 | GLAXOSMITHKLINE | Valve for aerosol container |
Aug, 2018
(5 years ago) | |
|
US7107986 (Pediatric) | GLAXOSMITHKLINE | Dispenser with doses' counter |
Dec, 2018
(5 years ago) | |
|
US6431168 (Pediatric) | GLAXOSMITHKLINE | Dispenser with doses′ counter |
Dec, 2018
(5 years ago) | |
|
US7350676 (Pediatric) | GLAXOSMITHKLINE | Valve for aerosol container |
Feb, 2019
(5 years ago) | |
| US9861771 | GLAXOSMITHKLINE | Device housing for an aerosol container |
Oct, 2020
(3 years ago) | |
| US6743413 | GLAXOSMITHKLINE | Suspension aerosol formulations |
Jun, 2021
(2 years ago) | |
|
US6743413 (Pediatric) | GLAXOSMITHKLINE | Suspension aerosol formulations |
Dec, 2021
(2 years ago) | |
| US7832351 | GLAXOSMITHKLINE | Actuation indicator for a dispensing device |
Jun, 2023
(10 months ago) | |
|
US7832351 (Pediatric) | GLAXOSMITHKLINE | Actuation indicator for a dispensing device |
Dec, 2023
(4 months ago) | |
| US7500444 | GLAXOSMITHKLINE | Actuation indicator for a dispensing device |
Feb, 2026
(1 year, 10 months from now) | |
|
US7500444 (Pediatric) | GLAXOSMITHKLINE | Actuation indicator for a dispensing device |
Aug, 2026
(2 years from now) | |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 19 April, 2001
Treatment: The treatment or prevention of bronchospasm in adults and children 4 years of age and older with reversible obstructive airways disease and the prevention of exercised-induced bronchospasm in patients...
Dosage: AEROSOL, METERED;INHALATION
VENTOLIN HFA family patents
24. Veramyst patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7101866 | GLAXOSMITHKLINE | Anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6858596 | GLAXOSMITHKLINE | Formulation containing anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
| US7541350 | GLAXOSMITHKLINE | Formulation containing anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
| US9320862 | GLAXOSMITHKLINE | Fluid dispensing device |
Nov, 2024
(6 months from now) | |
| US8062264 | GLAXOSMITHKLINE | Fluid dispensing device |
Apr, 2026
(1 year, 11 months from now) | |
| US8752543 | GLAXOSMITHKLINE | Fluid dispensing device |
Apr, 2026
(1 year, 11 months from now) | |
| US8347879 | GLAXOSMITHKLINE | Fluid dispensing device |
Jul, 2028
(4 years from now) | |
| US8147461 | GLAXOSMITHKLINE | Fluid dispensing device |
Oct, 2028
(4 years from now) | |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 27 April, 2007
Treatment: The treatment of the symptoms of seasonal and perennial allergic rhinitis in patients 2 years of age and older; Treatment of rhinitis comprising the nasal application of a pharmaceutical formulation a...
Dosage: SPRAY, METERED;NASAL
VERAMYST family patents
25. Wellbutrin Sr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5763493 | GLAXOSMITHKLINE | Stabilized pharmaceutical |
Aug, 2013
(10 years ago) | |
| US5358970 | GLAXOSMITHKLINE | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
Aug, 2013
(10 years ago) | |
| US5427798 | GLAXOSMITHKLINE | Controlled sustained release tablets containing bupropion |
Aug, 2013
(10 years ago) | |
| US5731000 | GLAXOSMITHKLINE | Stabilized pharmaceutical composition containing bupropion |
Aug, 2013
(10 years ago) | |
Drugs and Companies using BUPROPION HYDROCHLORIDE ingredient
Market Authorisation Date: 04 October, 1996
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
WELLBUTRIN SR family patents
26. Zejula patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8436185 | GLAXOSMITHKLINE | Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide |
Apr, 2029
(4 years from now) | |
| US8071623 | GLAXOSMITHKLINE | Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors |
Mar, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8143241 | GLAXOSMITHKLINE | DNA damage repair inhibitors for treatment of cancer |
Aug, 2027
(3 years from now) | |
| US8071579 | GLAXOSMITHKLINE | DNA damage repair inhibitors for the treatment of cancer |
Aug, 2027
(3 years from now) | |
| US8859562 | GLAXOSMITHKLINE | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer |
Aug, 2031
(7 years from now) | |
| US11091459 | GLAXOSMITHKLINE | Niraparib compositions |
Mar, 2038
(13 years from now) | |
| US11673877 | GLAXOSMITHKLINE | Niraparib compositions |
Mar, 2038
(13 years from now) | |
| US11730725 | GLAXOSMITHKLINE | Niraparib formulations |
Jan, 2039
(14 years from now) | |
Drugs and Companies using NIRAPARIB TOSYLATE ingredient
Market Authorisation Date: 26 April, 2023
Treatment: A method of treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer associated with homologous recombination deficiency (hrd) positive status; A method of treatment of recurrent ov...
Dosage: TABLET;ORAL
ZEJULA family patents
27. Zyban patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5427798 | GLAXOSMITHKLINE | Controlled sustained release tablets containing bupropion |
Aug, 2013
(10 years ago) | |
| US5358970 | GLAXOSMITHKLINE | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
Aug, 2013
(10 years ago) | |
| US5763493 | GLAXOSMITHKLINE | Stabilized pharmaceutical |
Aug, 2013
(10 years ago) | |
| US5731000 | GLAXOSMITHKLINE | Stabilized pharmaceutical composition containing bupropion |
Aug, 2013
(10 years ago) | |
Drugs and Companies using BUPROPION HYDROCHLORIDE ingredient
Market Authorisation Date: 14 May, 1997
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
ZYBAN family patents